Randomized Phase II/III Adjuvant Trial Evaluating Feasibility of Standard (A) vs. Customized Treatment (B) in Stage II or Stage IIIA Non-N2, Non-Squamous Non Small Cell Lung Cancer (NSCLC).

Trial Profile

Randomized Phase II/III Adjuvant Trial Evaluating Feasibility of Standard (A) vs. Customized Treatment (B) in Stage II or Stage IIIA Non-N2, Non-Squamous Non Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms TASTE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 09 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top